Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodulin for hospitalized community-acquired pneumonia including COVID-19 (phase III)
2022-000736-37Phase 3Active
- Sponsor
- Biotest AG
- Start
- May 2022
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community-acquired pneumonia (CAP) and coronavirus pneumonia comparing Trimodulin + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Composite primary endpoint: Deterioration / mortality rate. Started May 2022; status: active.
02
Drugs
Pentaglobin
03
Conditions
community-acquired pneumonia (CAP)coronavirus pneumonia
Beyond the preview
Go deeper on 2022-000736-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000736-37.